<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01902342</url>
  </required_header>
  <id_info>
    <org_study_id>CES01</org_study_id>
    <nct_id>NCT01902342</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Investigate the Influence of CES1 Polymorphism on Oseltamivir</brief_title>
  <acronym>CES1</acronym>
  <official_title>A Clinical Trial to Investigate the Influence of CES1 Polymorphism on Pharmacokinetic Characteristics of Oseltamivir in Healthy Korean Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigate genetic variability of CES1 gene on pharmacokinetics of oseltamivir in healthy
      Korean volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oseltamivir pharmacokinetic parameters</measure>
    <time_frame>Up to 0 to 48 h post dose</time_frame>
    <description>Maximum plasma concentration (Cmax), Area under the plasma concentration curve (AUClast and AUCinf)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oseltamivir carboxylate pharmacokinetic parameters</measure>
    <time_frame>Up to 0 to 48 h post dose</time_frame>
    <description>Maximum plasma concentration (Cmax), Area under the plasma concentration curve (AUClast and AUCinf)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other oseltamivir pharmacokinetic parameters</measure>
    <time_frame>Up to 0 to 48 h post dose</time_frame>
    <description>first time to reach Cmax (tmax), terminal half-life (t1/2z), apparent clearance (CL/F), apparent renal clearance (CLR/F), metabolic ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other oseltamivir carboxylate pharmacokinetic parameters</measure>
    <time_frame>Up to 0 to 48 h post dose</time_frame>
    <description>first time to reach Cmax (tmax), terminal half-life (t1/2z), apparent clearance (CL/F), apparent renal clearance (CLR/F), metabolic ratio</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>CES1 gene variant group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oseltamivir 75 mg 1 cap</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CES1 gene wild type group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oseltamivir 75 mg 1 cap</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oseltamivir 75 mg 1 cap</intervention_name>
    <arm_group_label>CES1 gene variant group</arm_group_label>
    <arm_group_label>CES1 gene wild type group</arm_group_label>
    <other_name>Tamiflu</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy subjects:

          1. Agreement with written informed consent

          2. Adult healthy male or female subject age 20 to 45

        Exclusion Criteria:

          1. Clinically significant, active gastrointestinal system, cardiovascular system,
             pulmonary system, renal system, endocrine system, blood system, digestive system,
             central nervous system, mental disease or malignancy

          2. Medication with any drug which may affect the pharmacokinetics of oseltamivir within
             14 days

          3. Previously donate whole blood within 30 days or Previously participated in other trial
             within 60 days

          4. Subject with known for hypersensitivity reactions to oseltamivir

          5. Subject who perform contraception during study periods

          6. Female woman who are pregnant or are breast feeding

          7. An impossible one who participates in clinical trial by investigator's decision
             including laboratory test result
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyoung Soo Lim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital Clinical Trial Center</name>
      <address>
        <city>Seoul</city>
        <zip>110-768</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2013</study_first_submitted>
  <study_first_submitted_qc>July 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2013</study_first_posted>
  <last_update_submitted>May 15, 2014</last_update_submitted>
  <last_update_submitted_qc>May 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oseltamivir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

